In the current study, we observed that hepatic expression of the FGF21 coreceptor35, KLB, is reduced in human NAFLD patients, as well as in obese mice, consistent with decreased FGF21 signaling. Here, KLB is linked to metabolic dysfunction-associated steatotic liver disease.